# Systematic Review of Surgical Outcomes and Complications of Extracorporeal Septoplasty and Its Modifications

Emily A. Spataro MD<sup>1</sup>, Mikhail Saltychev MD PhD<sup>2</sup>, Cherian K. Kandathil<sup>3</sup>, Sam P. Most MD<sup>3</sup>

# AFFILIATIONS

<sup>1</sup> Division of Facial Plastic and Reconstructive Surgery, Washington University School of Medicine, St. Louis, Missouri.

<sup>2</sup>Department of Physical and Rehabilitation Medicine, Turku University Hospital and University of Turku, Turku, Finland.

<sup>3</sup> Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology-Head & Neck Surgery, Stanford University School of Medicine, Stanford, California.

## ADDRESS FOR CORRESPONDENCE

Sam P. Most MD.

Division of Facial Plastic and Reconstructive Surgery, Department of Otolaryngology- Head and Neck Surgery, Stanford University School of Medicine, 801 Welch Road, Stanford, CA 94305. smost@stanford.edu

## FUNDING

None to declare

# **CONFLICT OF INTEREST**

None to declare

# **Prospero ID**

2018098698

# KEYWORDS

Systematic review; septoplasty; nasal obstruction; nasal cosmesis; surgery outcome

Word Count: 2462

#### Abstract

**Importance:** While extracorporeal septoplasty (ECS) and its modifications has been previously studied, to our knowledge, no systematic review of surgical outcomes and complications of this technique has been performed.

**Objective:** To evaluate the evidence of surgical outcomes and complications of ECS (including modified techniques) to treat severe L-strut septal deviation defined as deviation within 1.0 cm of the caudal or dorsal septum.

**Data Sources:** Medline, Embase, Cinahl, Central, Scopus, and Web of Science databases and reference lists were searched for clinical and observational studies.

**Study Selection:** Selection criteria were defined according to the population, intervention, comparison, and outcome (PICO) framework. Relevant studies were selected by 2 independent reviewers based on abstracts and full texts.

**Data Extraction and Synthesis:** Data were extracted using standardized lists chosen by the authors according to Cochrane Collaboration guidelines. Data were collected and synthesized with ranges reported, as well as assessment of bias and heterogeneity when applicable.

**Main Outcomes and Measures:** Outcomes assessed included functional nasal airway improvement by objective measurements and subjective measurements (NOSE scores and VAS scores); complications including bleeding, infection, dorsal irregularities, and other functional or cosmetic deficits, as well as revision surgery rates.

**Results:** Of 291 records initially obtained, 31 were considered relevant after review according to PRISMA guidelines. All studies except 1 randomized control trial were observational in nature, with 21 retrospective studies and 9 prospective studies. Conventional ECS was performed in 16 studies, and modified ECS performed in 15 studies. Sample size varied from 10 to 567, and

average age varied from 22.5 to 46 years. Less than half (14 of 31) of these studies were of good methodology. Meta-analysis was performed on 5 studies reporting change in NOSE scores, with pooled effect of -60.0 (95% CI -67.8 to -52.2) points, but heterogeneity was high with  $I^2$ =96%. When comparing complications between modified and conventional ECS, the relative risk for infections was 1.25 (95% CI 0.47 to 3.35), for bleeding was 0, for nasal dorsal irregularities 0.33 (95% CI 0.17 to 0.60), for other cosmetic complications 4.8 (95% CI 0.97 to 23.8), for other functional complications 0.61 (95% CI 0.27 to 1.37), and for revision operations 0.71 (95% CI 0.41 to 1.21).

**Conclusions and Relevance:** Of the 31 studies included in this systematic review, less than half were of good methodology, and a significant level of heterogeneity was found regarding type of outcome measure used and reporting of complications. To improve the level of evidence, better study methodology, standardization of surgical outcomes measures and reporting of complications is needed.

# **Key Points**

**Question:** Is ECS (including modified techniques) effective in the treatment of severe L-strut septal deviation?

**Findings**: In this systematic review of 31 studies, a meta-analysis of 5 studies reporting change in Nasal Obstruction Symptom Evaluation scores, with pooled effect of -60.0 (95% CI -67.8 to - 52.2) points, but heterogeneity was high with  $I^2=96\%$ .

**Meaning:** These findings highlight that although ECS and its modifications are likely effective methods to reduce nasal airway obstruction for deviations of the septal L-strut, standardized reporting of outcomes and sound methodology of study design is needed.

#### INTRODUCTION

It is estimated that septal deformities are present in 77-90% of the general population, and the best treatment depends on the location and severity of the septal deviation<sup>1-5</sup>. Standard endonasal septoplasty approaches are beneficial for most patients with mild to moderate middle or posterior septal deviations, however this is not as effective for more severe deformities<sup>5,6</sup>. Severe deviations, especially if located in the anterocaudal septum makes repair more challenging<sup>7-11</sup>. Caudal septal deviation causing obstruction of the internal nasal valves often results in aesthetic deformity as well, and repair of the septum in this location places nasal tip support.<sup>12</sup>

Numerous repair techniques have been described for deformities of the caudal septum such as swinging door, septal translocation, cartilage scoring, grafting techniques, septal extension grafts, and replacement grafts<sup>13-15</sup>. Metzenbaum described the swinging door technique as early as 1929, wherein a vertical piece of septal cartilage is removed from deviated side and the caudal septum is repositioned to midline<sup>13</sup>. Scoring incisions, spreader grafts, morselization, tongue in groove stabilization, batten grafts, polydioxanone (PDS) foil matrix for reconstruction with native septal cartilage, cartilage grafts, and grafts have also been described<sup>15</sup>.

Extracorporeal septoplasty (ECS) for severe deviations of dorsal and caudal septum was first described in 1952 by King and Ashley<sup>16</sup>. This technique entails complete removal and replacement of the cartilaginous septum, held in place with transeptal sutures<sup>16</sup>. This technique has been most extensively described by Gubisch<sup>17</sup>. In their large case series, the revision rate

was 9%, but decreased by use of camouflage grafts to mask settling at rhinion, as it is difficult to reform the bony-cartilaginous attachment at the keystone<sup>17</sup>. Modifications of the ECS technique include use of PDS plates introduced in the 1980s to further stabilize implanted cartilage<sup>18-23</sup>. Other modifications include grafting techniques, limited dorsal septal removal, and methods to better secure the cartilage to reduce dorsal irregularities<sup>17-27</sup>.

The objective of this study was to investigate evidence of the safety and effects of extracorporeal septoplasty (including modified techniques) to treat severe L-strut septal deviation, defined as deviation occurring within 1.0 cm of the caudal or dorsal septum.

#### **METHODS**

This review protocol was based the Cochrane Handbook for Systematic Reviews of Interventions<sup>28</sup>. Inclusion and exclusion criteria based on the population, intervention, comparison, and outcome (PICO) framework, described below.

<u>Population:</u> Adults (>=18 years) with nasal obstruction due to severe L-strut caudal septal deviation, excluding other causes of nasal obstruction such as non-L strut septal deviation, lateral nasal wall insufficiency, turbinate hypertrophy, nasal polyps, intranasal masses, rhinitis, and sinusitis.

<u>Type of studies:</u> Clinical and observational studies published in peer-reviewed academic journals with abstracts available without restrictions on language or time of publication. Excluding pilot

reports, case reports, case series (<5 patients), descriptive publications on surgical techniques, theses, conference proceedings, letters (except research letters and brief reports), and editorials.

<u>Intervention</u>: Extracorporeal septoplasty or its modifications including anterior septal reconstruction with or without turbinoplasty. Excluding standard septoplasty with or without turbinoplasty, and sinus surgery. Standard septoplasty is defined as a surgical procedure to remove a variable portion of the mid-posterior bony and cartilaginous nasal structure leaving in place a minimum of 1.0 cm dorsal and caudal L-strut. An extracorporeal septoplasty and its modification may involve total or partial removal and reconstruction of the cartilaginous septum which includes the L-strut.

<u>Comparison:</u> Rates of complications in reference populations. Pre- and post-surgery results within the sample. If control group available, comparison with no surgery, other surgery, or intranasal medications (e.g., steroids).

<u>Outcome:</u> Rate of complications. Change in nasal obstruction severity level before and after the surgery or difference between groups in that change.

#### Data sources and searches

The MEDLINE (via PubMed), Embase, Cinahl, Web of Science, and Scopus databases were searched in April 2018. When searching on Medline, the following clause was used: extracorporeal AND (septoplasty\* OR septum) NOT (case [TI] OR protocol[TI] OR pilot[TI] OR reliability[TI] OR validity[TI] OR sinus[TI] OR sinuit\*[TI] OR cardio\*[TI] OR vascul\*[TI] OR arter\*[TI] OR ventricul\*[TI] OR myocard\*[TI] OR heart[TI] OR atrial[TI] OR child\*[TI] OR neonat\*[TI]) AND (hasabstract[text] AND "humans"[MeSH Terms])

The clause was adjusted when searching on other databases. In order to avoid missing any potentially relevant studies, the search clauses were left as generic as possible and a refining search was conducted manually. The references of identified articles and reviews were also checked for relevancy.

#### **Study selection**

Two independent reviewers (EAS and CKK) screened titles and abstracts of articles and assessed the full texts of potentially relevant studies according to PRISMA guidelines (Figure 1). Disagreements between the reviewers were resolved by consensus or by a third reviewer (MS).

#### Assessment of risk of systematic bias

The methodological quality of the included trials was rated according to the Guidance for Assessing the Quality of Before-After (Pre-Post) Studies with No Control Group<sup>29</sup>. The following 12 domains were evaluated: 1 – Study question, 2 – Eligibility criteria and study population; 3 – Study participants representative of clinical populations of interest; 4 – All eligible participants enrolled; 5 – Sample size; 6 – Intervention clearly described; 7 – Outcome measures clearly described, valid, and reliable; 8 – Blinding of outcome assessors; 9 – Follow-up rate; 10 – Statistical analysis; 11 – Multiple outcome measures; and 12 – Group-level interventions and individual-level outcome efforts. Individual criteria were valued as 'yes', 'no', or 'NA' (Not applicable or not reported). The total quality was valued as 'poor', 'fair', or 'good'.

#### **Data extraction**

The potentially relevant data were extracted of the records by one reviewer using a predefined structured form (CKK). The extracted data were then checked by a second reviewer (EAS).

#### Statistical analysis

The interrater reliability for review of screened records by independent authors were assessed using the kappa (K) statistic. To quantify the pooled effect size of included studies, a random effects meta-analysis was used as a more natural choice than fixed effects in the context of medical data obtained from very different sources. The test for heterogeneity was conducted using the I<sup>2</sup> statistic describing the percentage of variation across studies originating rather from heterogeneity than from chance. The results were reported along with their 95% confidence intervals (95% CI) or two-tailed *p*-values when appropriate (level of *p*-value significance set at =<0.005). A non-standardized ('raw') mean of difference in change in NOSE total scores were calculated. A standardized mean of difference was calculated when several outcome measures were involved into the same analysis.

The pre-/post-correlation coefficient was set to 0.6. To ensure that the overall result of the analysis is robust to the use of imputed correlation coefficients, a sensitivity analysis was conducted setting the correlation coefficient at 0.8. In the initial synthesis calculations  $7^{26,27,30-33}$  studies that reported NOSE scores,  $4^{21,27,34,35}$  that reported visual analogue scores, and  $2^{31,36}$  that reported acoustic rhinomanometry were included. Results were reported as means, 95% CI, and p-values.

Of the estimates reported by Surowitz et al.<sup>27</sup>, the total NOSE scores for the longest follow-up of 225 days was included and other estimates excluded from the meta-synthesis. The study by Asher et al.<sup>30</sup> was excluded from meta-synthesis as total NOSE scores were not reported. Additionally, studies by Jang et al.  $(2009)^{34}$  and Code et al.<sup>35</sup> were excluded as variances were not reported along with average estimates. For the estimates reported by Mobley et al.<sup>37</sup>, means and SDs were obtained from median and ranges as follows: Mean = (low end of range + 2 x median + high end of range)/4 and Variance =  $1/12 \times [(low end of range - 2 \times median + high end of range - low end of range)^2]$ . This way, for that study, preoperative and postoperative mean NOSE total scores were 14.5 (1.41) and 3.0 (1.17), respectively.

The potential publication bias was evaluated by Egger's test for asymmetry of the funnel plot (test for the Y intercept = 0 from the linear regression of normalized effect estimate against precision), where the trim-and-fill method was used to impute studies into funnel plot to correct asymmetry.

All calculations for the meta-analysis were performed using Comprehensive Meta-Analysis CMA, 3<sup>rd</sup> Edition, available from www.meta-analysis.com, and Microsoft Excel® 2010.

#### RESULTS

All studies except 1 randomized control trial were observational in nature, with 21 retrospective studies and 9 prospective studies. Conventional ECS was performed in 16 studies<sup>20,22,24,25,35-46</sup>, while the other 15 were modifications of this technique<sup>21,26,27,30-34,47-53</sup>, although heterogeneity of

each technique used for every study was present. Sample size varied from 10 to 567, and average age varied from 22.5 to 46 years (Table 1).

#### **Risk of systematic bias**

Of the included 31 studies<sup>20-22,24-27,30-53</sup>, methodologically, 14 were considered to be  $good^{21,26,27,31,33,35-37,40,45,48,50-52}$ , 11 were considered poor<sup>22,24,25,38,39,41,42,46,47,49,53</sup>, and 6 were considered fair<sup>20,30,32,34,43,44</sup> (eTable 1).

#### Patient-reported outcome measures

The initial meta-analysis was conducted including seven studies<sup>21,27,31-33,37</sup> that reported complete data for NOSE or VAS scores (Table 2, Figure 2A). The pooled standardized difference in means was -5.8 (95% CI -7.6 to -4.0) indicating a large effect size. The heterogeneity was  $I^2$ =97%. While there was potential publication bias (Egger's regression intercept' *p*-value 0.026), no trim-and-fill imputations were needed. There was a slight change in results after excluding Mobley et al.<sup>37</sup>, the only paper on conventional ECS (Figure 2B): -5.1 (95% CI -6.8 to 3.4). For clearer interpretation, the final meta-analysis was conducted on a raw difference of means instead of a standardized one. Excluding one study<sup>21</sup> reporting only VAS scores, based on the results of five studies<sup>26,27,31-33</sup> on modified ECS only, the change in total NOSE score was -60.0 (95% CI -67.8 to -52.2) points (Figure 2C). The heterogeneity was high  $I^2$ =96%.

#### **Objective outcome measures**

Two studies<sup>31,36</sup> reported both pre- and post-operative objective outcomes, as well as standard deviations (Table 3). Three other studies<sup>40,50,51</sup> reported objective outcomes, but did not report full data to allow pre- and post-operative comparison. In Garcia et al<sup>31</sup>, the mean postoperative changes in minimum cross-sectional area using acoustic rhinometry increased by 0.33 (95% CI 0.21 to 0.44) cm<sup>2</sup> before constriction and 0.30 (95% CI 0.18 to 0.42) cm<sup>2</sup> after constriction. Serna et al.<sup>36</sup>, reported the changes in nasal flow and nasal resistance using active anterior rhinomanometry: the smallest estimates of changes were 321 (95% CI 253 to 389) cm<sup>3</sup>/s and - 0.09 (95% CI -0.11 to -0.08) Pas/cm<sup>3</sup>, respectively.

#### **Risks of complications or revision surgery**

Rates of complications and/or revision surgery were reported in 24 studies (eTable 2): infection rates ranged from 0-8.9%; bleeding from 0-6.25%; dorsal irregularities from 0-12.5%; and revision surgery from 0-14%. Of the 11 studies<sup>21,27,30,32-34,49-53</sup> on modified ECS (pooled n=695, only including groups of interest), there were 7 infections (1.0%), no bleeding events, 12 nasal dorsal irregularities (1.7%), 6 other cosmetic complications (0.86%), 8 other functional complications (1.2%), and 19 revision operations (2.7%). Of the 13 studies<sup>20,22,24,25,35,38-44,46</sup> on conventional ECS (pooled n=1119, only including groups of interest), there were 9 infections (0.80%), 6 bleeding events (0.54%), 59 nasal dorsal irregularities (5.3%), 2 other cosmetic complications (1.9%), and 43 revision operations (3.8%). When comparing modified versus conventional ECS, the relative risk for infections was 1.25 (95% CI 0.47 to 3.35), for bleeding was 0, for nasal dorsal irregularities 0.33 (95% CI 0.17 to 0.60), for other cosmetic complications 4.8 (95% CI 0.97 to 23.8), for other functional

complications 0.61 (95% CI 0.27 to 1.37), and for revision operations 0.71 (95% CI 0.41 to 1.21).

#### DISCUSSION

In this systematic review, 31 studies were included to assess surgical outcomes and complications of ECS and its modifications. When evaluating surgical outcomes, final metaanalysis could only be performed using five studies<sup>26,27,31-33</sup> all of modified ECS techniques reporting NOSE outcomes, as most studies used variable methods to report results. While the meta-analysis of the five studies showed a change in total NOSE score of -60.0 (95% CI -67.8 to -52.2) points, indicating both a clinically and statistically significant improvement of nasal obstruction, as this was higher than the NOSE MCID<sup>54</sup>, the heterogeneity was high (I<sup>2</sup>=96%). Additionally, less than half of the studies (14 of 31) were considered to be of "good" methodology according to the Guidance for Assessing the Quality of Before-After (Pre-Post) Studies with No Control Group<sup>29</sup>(e Table 1). These findings highlight that although ECS and its modifications are likely effective methods to reduce nasal airway obstruction for deviations of the septal L-strut, standardized reporting of outcomes and sound methodology of study design is needed.

Objective outcomes measures were reported in 5 studies<sup>31,36,40,50,51</sup>, however only 2 studies<sup>31,36</sup> provided data required for pre- and post-operative assessment of outcomes (Table 3). These results increased minimum cross-sectional area by 0.33 (95% CI 0.21 to 0.44) cm<sup>2</sup> before constriction and 0.30 (95% CI 0.18 to 0.42) cm<sup>2</sup> after constriction<sup>31</sup>, increased nasal flow of 321 (95% CI 253 to 389) cm<sup>3</sup>/s and decreased nasal of -0.09 (95% CI -0.11 to -0.08) Pas/cm<sup>3 36</sup>. While these results show improvement in these objective parameters, it is difficult to draw

conclusions on the efficacy of ECS using these measures based on only single studies with small sample sizes (10 and 26 patients, respectively).

Complication and/or revision surgery rates were reported in 24 studies, 11 using the modified ECS <sup>21,27,30,32-34,49-53</sup> and 13 using conventional ECS<sup>20,22,24,25,35,38-44,46</sup>. Pooled data analysis comparing modified versus conventional ECS resulted in statistically significant difference in the relative risk of nasal dorsal irregularities 0.33 (95% CI 0.17 to 0.60). Dorsal irregularities were also the most common complication reported among the conventional ECS group (5.3%). Thus, as many of the modified ECS techniques aim to reduce this most common complication of conventional ECS, these results show their effectiveness in achieving this goal. Other complications, such as infection, bleeding, other cosmetic or functional complication and revision surgery rates were not found to be significantly different between the two groups.

As stated previously, limitations of this study include the heterogeneity of outcomes reporting in the included studies of conventional and modified ECS, as well as the low number of studies employing good methodology. While the 5 studies included for meta-analysis showed significant improvement in nasal obstruction using ECS, there was also a high level of heterogeneity among them. These findings point to the need for improved standardization of outcomes reporting for nasal airway procedures. Additionally, as the most common complication of these procedures would be considered cosmetic (dorsal irregularities), it also highlights the need for assessing both functional and cosmetic outcomes even when only performing functional nasal surgery. Thus outcomes measures such as the newly developed Standardized Cosmesis and Health Nasal Outcomes Survey (SCHNOS), would be ideal for future reporting of standard or modified ECS outcomes.<sup>55,56</sup>

# CONCLUSION

Of the 31 studies included in this systematic review, a majority were of fair or poor

methodology, and a significant level of heterogeneity was found regarding type of functional

and/or cosmetic outcome measure used and reporting of complications. To improve the level of

evidence, better study methodology, standardization of surgical outcomes measures and

reporting of complications is needed.

# References

- 1. Walsh WE KR. Sinonasal anatomy, function and evaluation. In: Bailey BJ JJ, Newlands SD, ed. *Head and Neck Surgery—Otolaryngology*. 4th ed. Philadelphia, PA: Lippincot Williams & Wilkins; 2006:307-318.
- 2. Lupa M A, Becker SS, Becker DG. Septoplasty. In: Chiu AG PJ, Adappa ND, ed. *Atlas* of *Endoscopic Sinus abd Skull Base Surgery*. Vol Philadelphia, PA. Elsevier; 2019.
- 3. Gray LP. Deviated nasal septum. Incidence and etiology. *Ann Otol Rhinol Laryngol Suppl*. 1978;87(3 Pt 3 Suppl 50):3-20.
- 4. Mladina R, Cujic E, Subaric M, Vukovic K. Nasal septal deformities in ear, nose, and throat patients: an international study. *Am J Otolaryngol.* 2008;29(2):75-82.
- 5. Becker DG. Septoplasty and turbinate surgery. *Aesthetic surgery journal*. 2003;23(5):393-403.
- 6. Paradis J, Rotenberg BW. Open versus endoscopic septoplasty: a single-blinded, randomized, controlled trial. *Journal of otolaryngology head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale*. 2011;40 Suppl 1:S28-33.
- 7. Most SP. Analysis of outcomes after functional rhinoplasty using a disease-specific quality-of-life instrument. *Arch Facial Plast Surg.* 2006;8(5):306-309.
- 8. Most SP. Trends in functional rhinoplasty. Arch Facial Plast Surg. 2008;10(6):410-413.
- 9. Rohrich RJ, Hollier LH. Use of spreader grafts in the external approach to rhinoplasty. *Clin Plast Surg.* 1996;23(2):255-262.
- 10. Sheen JH. Spreader graft: a method of reconstructing the roof of the middle nasal vault following rhinoplasty. *Plastic and reconstructive surgery*. 1984;73(2):230-239.


- Yoo S, Most SP. Nasal airway preservation using the autospreader technique: analysis of outcomes using a disease-specific quality-of-life instrument. *Arch Facial Plast Surg.* 2011;13(4):231-233.
- 12. Most SP, Rudy SF. Septoplasty: Basic and Advanced Techniques. *Facial Plast Surg Clin North Am.* 2017;25(2):161-169.
- 13. METZENBAUM M. REPLACEMENT OF THE LOWER END OF THE DISLOCATED SEPTAL CARTILAGE VERSUS SUBMUCOUS RESECTION OF THE DISLOCATED END OF THE SEPTAL CARTILAGE. *Archives of Otolaryngology*. 1929;9(3):282-296.
- 14. Sedwick JD, Lopez AB, Gajewski BJ, Simons RL. Caudal septoplasty for treatment of septal deviation: aesthetic and functional correction of the nasal base. *Arch Facial Plast Surg.* 2005;7(3):158-162.
- 15. Haack J, Papel ID. Caudal septal deviation. *Otolaryngol Clin North Am.* 2009;42(3):427-436.
- 16. King ED, Ashley FL. The correction of the internally and externally deviated nose. *Plast Reconstr Surg (1946).* 1952;10(2):116-120.
- 17. Gubisch W. The extracorporeal septum plasty: a technique to correct difficult nasal deformities. *Plastic and reconstructive surgery*. 1995;95(4):672-682.
- 18. Petropoulos I, Nolst Trenite G, Boenisch M, Nousios G, Kontzoglou G. External septal reconstruction with the use of polydioxanone foil: our experience. *Eur Arch Otorhinolaryngol.* 2006;263(12):1105-1108.
- 19. Boenisch M, Nolst Trenite GJ. Reconstructive septal surgery. *Facial plastic surgery : FPS*. 2006;22(4):249-254.
- 20. Gerlinger I, Kárász T, Somogyvári K, et al. Extracorporal septal reconstruction with polydioxanone foil. *Clinical Otolaryngology*. 2007;32(6):465-470.
- Jang YJ, Kwon M. Modified extracorporeal septoplasty technique in rhinoplasty for severely deviated noses. *The Annals of otology, rhinology, and laryngology*. 2010;119(5):331-335.
- 22. Tweedie DJ, Lo S, Rowe-Jones JM. Reconstruction of the nasal septum using perforated and unperforated polydioxanone foil. *Arch Facial Plast Surg.* 2010;12(2):106-113.
- 23. Boenisch M, Nolst Trenite GJ. Reconstruction of the nasal septum using polydioxanone plate. *Arch Facial Plast Surg.* 2010;12(1):4-10.
- 24. Şenyuva C, Yücel A, Aydin Y, Okur I, Güzel Z. Extracorporeal septoplasty combined with open rhinoplasty. *Aesthetic Plastic Surgery*. 1997;21(4):233-239.
- 25. Gubisch W. Extracorporeal septoplasty forlhe markedly deviated septum. *Archives of Facial Plastic Surgery*. 2005;7(4):218-226.
- 26. Most SP. Anterior septal reconstruction Outcomes after a modified extracorporeal septoplasty technique. *Archives of Facial Plastic Surgery*. 2006;8(3):202-207.
- 27. Surowitz J, Lee MK, Most SP. Anterior Septal Reconstruction for Treatment of Severe Caudal Septal Deviation: Clinical Severity and Outcomes. *Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2015;153(1):27-33.
- 28. Higgins JPT GS. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0. [updated March 2011]. In: The Cochrane Collaboration; 2011.
- 29. National Heart L, and Blood Institute; National Institutes of Health; U.S. Department of Health and Human Services. Quality Assessment Tool for Before-After (Pre-Post)


Studies With No Control Group. *Study Quality Assessment Tools* <u>https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools</u>. Accessed Novemebr 14, 2018.

- 30. Asher SA, Kakodkar AS, Toriumi DM. Long-term outcomes of subtotal septal reconstruction in rhinoplasty. *JAMA Facial Plastic Surgery*. 2018;20(1):50-56.
- 31. Garcia LBS, de Oliveira PW, de Aguiar Vidigal T, de Magalhães Suguri V, de Paula Santos R, Gregório LC. Caudal septoplasty: Efficacy of a surgical techniquepreliminnary report. *Brazilian Journal of Otorhinolaryngology*. 2011;77(2):178-184.
- 32. Kayabasoglu G, Nacar A, Yilmaz MS, Altundag A, Guven M. A novel method for reconstruction of severe caudal nasal septal deviation: Marionette septoplasty. *Ear, nose, & throat journal.* 2015;94(6):E34-40.
- 33. Loyo M, Markey JD, Gerecci D, et al. Technical Refinements and Outcomes of the Modified Anterior Septal Transplant. *Jama Facial Plastic Surgery*. 2018;20(1):31-36.
- 34. Jang YJ, Yeo NK, Wang JH. Cutting and suture technique of the caudal septal cartilage for the management of caudal septal deviation. *Archives of Otolaryngology Head and Neck Surgery*. 2009;135(12):1256-1260.
- 35. Gode S, Benzer M, Uslu M, Kaya I, Midilli R, Karci B. Outcome of In Situ Septoplasty and Extracorporeal Subtotal Septal Reconstruction in Crooked Noses: A Randomized Self-Controlled Study. *Aesthetic Plastic Surgery*. 2018;42(1):234-243.
- 36. Serna EM, Tapia FC. Extracorporeal septoplasty: variations of the technique. *Facial plastic surgery : FPS.* 2014;30(2):194-204.
- 37. Mobley SR, Long J. Extracorporeal Septoplasty: Assessing Functional Outcomes Using the Validated Nasal Obstruction Symptom Evaluation Score over a 3-Year Period. *Plastic and Reconstructive Surgery*. 2016;137(1):151E-163E.
- 38. Gevorgyan A, Smith O. Correcting a bent septum by a k-wire stabilization during an extracorporeal septal reconstruction. *Aesthetic plastic surgery*. 2013;37(4):698-703.
- 39. Kantas I, Balatsouras DG, Papadakis CE, Marangos N, Korres SG, Danielides V. Aesthetic reconstruction of a crooked nose via extracorporeal septoplasty. *Journal of otolaryngology - head & neck surgery = Le Journal d'oto-rhino-laryngologie et de chirurgie cervico-faciale.* 2008;37(2):154-159.
- 40. Karameşe M, Akdal O, Akatekin A, Koplay TG, Koplay M, Tosun Z. Extracorporeal Septoplasty Combined with Valve Surgery in Rhinoplasty Patients. *Annals of plastic surgery*. 2016;76(1):7-12.
- 41. Mendis D, Cheang PP, Glossop LP. Audit: patient reported outcomes of extracorporeal septorhinoplasty. *Rhinology*. 2013;51(1):88-92.
- 42. Numanoğlu A. External cantilever sling in septorhinoplasty: A new technique. *Plastic* and *Reconstructive Surgery*. 1997;100(1):250-256.
- 43. Rezaeian F, Gubisch W, Janku D, Haack S. New Suturing Techniques to Reconstruct the Keystone Area in Extracorporeal Septoplasty. *Plastic and reconstructive surgery*. 2016;138(2):374-382.
- 44. Rimmer J, Ferguson LM, Saleh HA. Versatile applications of the polydioxanone plate in rhinoplasty and septal surgery. *Arch Facial Plast Surg.* 2012;14(5):323-330.
- 45. Unsal O, Bozkurt G, Akpinar M, et al. Outcomes of Open-Approach Extracorporeal Septoplasty Without Simultaneous Rhinoplasty: Effects on Nasal Tip Projection and Rotation. *JAMA Otolaryngology-Head & Neck Surgery*. 2016;142(10):988-993.

- 46. Wilson MA, Mobley SR. Extracorporeal septoplasty: complications and new techniques. *Arch Facial Plast Surg.* 2011;13(2):85-90.
- 47. Andre RF, Vuyk HD. Reconstruction of dorsal and/or caudal nasal septum deformities with septal battens or by septal replacement: An overview and comparison of techniques. *Laryngoscope*. 2006;116(9):1668-1673.
- 48. Boulanger N, Baumann C, Beurton R, et al. Septorhinoplasty by disarticulation: Early assessment of a new technique for morphological correction of crooked noses. *Rhinology*. 2013;51(1).
- 49. Chang YL. Correction of difficult short nose by modified caudal septal advancement in Asian patients. *Aesthetic surgery journal.* 2010;30(2):166-175.
- 50. Lee SB, Jang YJ. Treatment outcomes of extracorporeal septoplasty compared with in situ septal correction in rhinoplasty. *JAMA facial plastic surgery*. 2014;16(5):328-334.
- 51. Persichetti P, Toto V, Segreto F, Signoretti M, Marangi GF. Modified Extracorporeal Septoplasty: Functional Results at 6-Year Follow-up. *Annals of plastic surgery*. 2016;76(5):504-508.
- 52. Sirinoglu H, Yesiloglu N, Ersoy B. A New Perspective for Spreader Graft Use in Severely Deviated Septum: Is Septal Continuity an Obligation for a Stable and Straight Nasal Septum? *Facial plastic surgery : FPS.* 2016;32(4):460-468.
- 53. Won TB, Kang JG, Jin HR. Management of post-traumatic combined deviated and saddle nose deformity. *Acta Oto-Laryngologica*. 2012;132(SUPPL. 1):S44-S51.
- 54. Stewart MG, Smith TL, Weaver EM, et al. Outcomes after nasal septoplasty: results from the Nasal Obstruction Septoplasty Effectiveness (NOSE) study. *Otolaryngology-head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery*. 2004;130(3):283-290.
- 55. Moubayed SP, Ioannidis JPA, Saltychev M, Most SP. The 10-Item Standardized Cosmesis and Health Nasal Outcomes Survey (SCHNOS) for Functional and Cosmetic Rhinoplasty. *JAMA facial plastic surgery*. 2018;20(1):37-42.
- 56. Kandathil CK, Saltychev M, Abdelwahab M, Spataro EA, Moubayed SP, Most SP. Minimal Clinically Important Difference of the Standardized Cosmesis and Health Nasal Outcomes Survey. *Aesthetic surgery journal*. 2019.

Figure 1. PRISMA flow-diagram





#### Figure 2. Forest plots

Figure 2 C: Jang et al 2010 excluded as not reporting NOSE score

Table I. Basic charact	leristics of u		1
		Mean age or	Gender,
Study	n	range (SD $^3$ or	%
		range), years	women
Modified extracorpo	real septopla	asty	
Andre 2006			• • • • •
(Netherlands) <sup>1</sup>	45	32.6	29%
Asher 2018 (USA)	144	37.3 (13.7)	72%
	177	57.5 (15.7)	1270
Boulanger 2013	35	31.0	45%
(France)			
Chang, 2010	41	23 to 59	NR
(China)		20 10 07	
Garcia	10	NR	40%
2011(Brazil)	10		4070
Jang 2010 <sup>2</sup>	27	21.4(11.5)	110/
(Korea)	27	31.4 (11.5)	11%
Jang 2009 <sup>2</sup>			
(Korea)	45	32.0 (17 to 63)	4%
Kayabasoglu			
$2015'(Turkey)^1$	78	34.76 (11.91)	NR
Lee 2014 (South	84	30.0	12%
Korea) <sup>1</sup>			
Loyo 2018 (USA)	71	46.0 (16 to 72)	68%
Most, 2006 (USA)	12	34.5 (18 to 51)	33%
Persichetti 2016	120	30.8 (19 to 58)	48%
(Italy)	120	50.8 (19 10 58)	40/0
Srinoglu 2016	16	2(5(10), 25)	(20/
(Turkey)	16	26.5 (18 to 35)	63%
Surowitz 2015			
(USA)	77	38.4 (17 to 66)	32%
Won 2012 (Korea)	25	40.0 (18 to 67)	8%
· · · · · · · · · · · · · · · · · · ·	-	40.0 (10 10 07)	070
Extracorporeal septo	ριαδιγ		
Gerlinger 2007	16	42.0 (22 to 66)	69%
(Austria)		· · · · ·	
Gevorgyan 2013	17	18 to 46	41%
(Canada)	- /		
Gode 2018	20	$27.5(18 \pm 27)$	20%
(Turkey)	20	27.5 (18 to 37)	2070
Gubisch, 2005	2110	ND	ND
(Germany)	2119	NR	NR
Kantas 2008			<i>c</i> 10 <i>i</i>
(Greece)	64	34.0	64%
Karamese 2016			
(Turkey)	19	30.47 (7.32)	32%
	16	ND	200/
Mendis 2013 (UK)	46	NR	39%

Table 1. Basic characteristics of the included studies

Mobley 2016	55	36.02 (15.20)	36%
Numanoglu 1996 (Turkey)	45	NR	NR
Rezaeian 2016 (Switzerland)	110 (58 + 52)	Median 37 (14 to 64)	39%
Rimmer 2012 (Australia)	102	36.5 (20 to 63)	32%
Senyuva 1997 (Turkey)	17	22.5 (19 to 33)	24%
Serna 2014 (Spain)	26	21 to 56	15%
Tweedie 2010 (UK)	17 <sup>5</sup>	Median 33 (15 to 56)	20%
Wilson 2011 (USA)	46	34.0 (16 to 72)	22%
Unsal 2016 (Turkey)	32	34.8 (10.5)	19%

<sup>1</sup>Only groups with septal replacement were included; <sup>2</sup> Jang 2009 ja Jang 2010 samples are partially overlapping; <sup>3</sup> Standard deviation; <sup>4</sup> Not reported; <sup>5</sup> The entire sample n=50

Study         Outcome         up, days         Me an         SD 2         Mea n         SD           Modified extracorporeal sector Asher 2018 1         NOSE Item1 $NOSE$ 1.3         1.0         0.9           Asher 2018 1         NOSE Item2 $1.3$ 1.0         0.9           NOSE Item3 $1.0$ 0.9         0.9           NOSE Item4 $1.4$ 0.7         1.0           NOSE Item5 $1.4$ 0.5         1.0           Garcia 2011         NOSE Item5 $83.$ $7.23$ $7.56$ $5.91$ Garcia 2011         NOSE total $180$ $85.$ $5.17$ $25.0$ $2.12$ Loyo 2018         NOSE total $162$ $76.$ $14.8$ $12.9$ $13.8$ Surowitz         NOSE total $68.$ $17.4$ $21.1$ $19.8$ Surowitz         NOSE total $225$ $68.$ $17.4$ $21.1$ $19.6$ Surowitz         NOSE total $225$ $68.$ $17.4$ $21.6$ $19.0$ Surowitz         NOSE total $225$ </th <th></th> <th></th> <th>Follow-</th> <th>1</th> <th>perative</th> <th>Postop</th> <th>perative</th>			Follow-	1	perative	Postop	perative
Modified extracorporeal septoplasty         an         n         n           Asher 2018 1         NOSE Item1         NOSE Item2         1.3         1.0         0.9           NOSE Item2         NOSE Item3         2.3         1.3         0.7         0.9           NOSE Item3         2.60         1.3         0.7         0.9           NOSE Item4         2.5         1.3         0.7         1.0           NOSE Item4         1         0.5         1.0           Sarcia 2011         NOSE Item5         2.2         1.3         0.4         0.8           Garcia 2011         NOSE Item5         180         85.         5.17         25.0         2.12           Loyo 2018         NOSE total         162         76.         14.8         12.9         13.8           Surowitz         NOSE total         22         68.         17.4         21.1         19.8           Surowitz         NOSE total         22         68.         17.4         21.1         19.8           Surowitz         NOSE 2015         22         68.         17.4         21.1         19.8           Surowitz         NOSE         22         68.         17.4         2.6         <	Study	Outcome	up, days	Me	$SD^2$	Mea	SD
Asher 2018 1NOSE Item12.31.31.00.9NOSE Item3NOSE Item32.602.31.30.70.9NOSE Item4NOSE Item42.51.30.71.0NOSE Item410.91.40.51.0NOSE Item51.02.21.30.40.8Garcia 2011 2015NOSE total6083. 487.237.565.91Kayabasoglu 2015NOSE total18085. 255.1725.02.12Loyo 2018 totalNOSE total162 2576.14.85 212.913.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total2257.21.82.12.6Surowitz 2015VAS 5427.21.81.41.8Jang 2009VAS 18060 to 1808.3 63.043.041.0Jang 2010VAS1956.01.92.61.0Extracorporeal septoplastyMOSE total6014. 5311.0 to 5.0 43.031.0 to 5.0 4				an	50	n	50
Asher 2018Item10.9NOSE Item2NOSE Item42602.31.30.70.9NOSE Item42602.51.30.71.0NOSE Item5101.91.40.51.0Carcia 2011 NOSE Item5NOSE Item52.21.30.40.8Garcia 2011 NOSE totalNOSE total60 4883. 07.23 7.567.565.91Kayabasoglu 2015NOSE total180 085. 05.17 025.02.12Loyo 2018 totalNOSE total14.55 22424.58Most 2006 totalNOSE total162 276. 714.8 212.913.8Surowitz 2015 totalNOSE total225 268. 217.4 221.119.8Surowitz 2015 totalVAS 542 27.21.82.1 2.62.6Surowitz 2015 totalVAS 560 to 180 48.0 43.68 41.4Jang 2009 Itag 2009VAS VAS60 to 180 48.3 1.03.141.0 to 5.0 4Jang 2010 Extracorporeal septoplastyMOSE total601.92.61.0Extracorporeal septoplasty14. 11.0 to 5.0 43.0 31.0 to 5.0 43.0 31.0 to 5.0 4	Modified extra		ptoplasty				T
NOSE Item22602.31.30.70.9NOSE Item32602.51.30.71.0NOSE Item51.91.40.51.0OSE Item51.91.40.51.0Garcia 2011 totalNOSE total6083. 487.237.565.91Kayabasoglu 2015NOSE total18085.5.1725.02.12Loyo 2018 Most 2006NOSE total162 total76. 214.55 22424.58Most 2006 Surowitz 2015NOSE total162 276. 214.8 212.913.8Surowitz 2015NOSE total22568. 217.4 221.119.8Surowitz 2015NOSE total2257.21.81.4 2.11.8Jang 2009 Itag 2009VAS 180 18060 68.3 180 63.141.0 1.0Jang 2010 Extracorporeal septoplasty195 6.01.92.61.0Mobley 2016 MOSE total6014. 11.011.0 to 5.0 43.0 31.0 to 5.0 4	Asher 2018 <sup>1</sup>			2.3	1.3	1.0	0.9
Item2 $0.9$ NOSE Item3 $260$ $2.5$ $1.3$ $0.7$ $1.0$ NOSE Item4 $1.9$ $1.4$ $0.5$ $1.0$ NOSE Item4 $2.2$ $1.3$ $0.4$ $0.8$ Garcia 2011 NOSE Item5NOSE Item5 $2.2$ $1.3$ $0.4$ $0.8$ Garcia 2011 NOSE totalNOSE Item5 $48$ $7.23$ $7.56$ $5.91$ Kayabasoglu 2015NOSE total $180$ 0 $85.$ $5.17$ 25 $25.0$ $2.12$ Loyo 2018 NoSE totalNOSE total $420$ 72 $72.$ 25 $14.55$ 24 $24.58$ Most 2006 NOSE totalNOSE total $162$ 7 $76.$ $14.8$ 7 $12.9$ $13.8$ Surowitz 2015NOSE total $225$ 28 $7.2$ $1.8$ $1.4$ 19.8 $19.0$ Surowitz 2015NOSE total $225$ $7.2$ $1.8$ $1.4$ 1.8 $1.8$ Surowitz 2015VAS $^5$ $42$ 104 $7.2$ $1.8$ $1.4$ 1.8 $1.8$ Jang 2009 Itang 2009VAS 180 $60$ to 180 $8.3$ $60$ to 180 $3.0^3$ $1.0$ to $5.0^4$ Jang 2010 Extracorporeal septoplasty $14.$ $108$ $11.0$ to $5.3^3$ $1.0$ to $5.0^4$ $10.0$			-		1.2	0.7	
NOSE Item3260 $2.5$ $1.3$ $0.7$ $1.0$ NOSE Item4 $1.9$ $1.4$ $0.5$ $1.0$ Sarcia 2011NOSE Item5 $2.2$ $1.3$ $0.4$ $0.8$ Garcia 2011NOSE total $60$ $83.$ $7.23$ $7.56$ $5.91$ Kayabasoglu 2015NOSE total $180$ $85.$ $5.17$ $25.0$ $2.12$ Loyo 2018NOSE total $420$ $72.$ $14.55$ $24$ $24.58$ Most 2006NOSE total $162$ $76.$ $14.8$ $12.9$ $13.8$ Surowitz 2015NOSE total $225$ $68.$ $17.4$ $21.1$ $19.8$ Surowitz 2015NOSE total $225$ $68.$ $17.4$ $21.1$ $19.8$ Surowitz 2015NOSE total $225$ $68.$ $17.4$ $21.1$ $19.8$ Surowitz 2015NOSE total $225$ $7.2$ $1.8$ $1.4$ $1.8$ Jang 2009VAS $180$ $60$ to $180$ $8.0$ $3.68$ $-14$ $-14$ Jang 2010VAS $195$ $6.0$ $1.9$ $2.6$ $1.0$ Extracorporeal septoplasty $14.$ $11.0$ to $5.3$ $1.0$ to $5.0.4$ $3.0.3$ $1.0$ to $5.0.4$				2.3	1.3	0.7	0.9
Item3260IIIIINOSE Item41.91.40.51.0NOSE Item51.02.21.30.40.8Garcia 2011 totalNOSE total6083. 487.237.565.91Kayabasoglu 2015NOSE total18085. 05.17 2525.02.12Loyo 2018 totalNOSE total42072. 2514.55 252424.58Most 2006 totalNOSE total162 276. 214.812.913.8Surowitz 2015NOSE total162 276. 214.812.913.8Surowitz 2015NOSE total22568. 217.421.1 2.619.8Surowitz 2015NOSE total22568. 217.415.8 2.119.0Surowitz 2015VAS 542 27.21.81.41.8Jang 2009VAS 18060 to 1808.0 41.41.8Jang 2010VAS 180608.0 1803.1410 to 5.0 4Jang 2016NOSE total6014. 1.0 to 5.31.0 to 5.0 43.0 31.0 to 5.0 4				2.5	1.2	0.7	
NOSE Item41.91.40.51.0NOSE Item52.21.30.40.8Garcia 2011 2015NOSE total60 4883. 487.237.565.91Kayabasoglu 2015NOSE total180 085. 05.17 25.02.12Loyo 2018 Most 2006NOSE total420 2572. 2514.55 2424.58Most 2006 DotalNOSE total162 276. 714.8 212.913.8Surowitz 2015 totalNOSE total22568. 217.4 221.119.8Surowitz 2015 totalNOSE total22568. 217.421.1 2.619.0Surowitz 2015 totalVAS 180427.2 21.81.4 2.11.8Jang 2009 Jang 2009VAS NOSE 18060 to 1808.0 43.681.0Jang 2010 LotalVAS1956.01.92.61.0Extracorporeal septoplasty1956.01.92.61.0 to 5.0 4			260	2.5	1.5	0.7	1.0
Item41.0NOSE Item52.21.30.4 $0.8$ Garcia 2011NOSE total6083. 487.237.565.91Kayabasoglu 2015NOSE total18085. 05.1725.02.12Loyo 2018NOSE total42072. 2514.552424.58Most 2006NOSE total16276. 714.812.913.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total2257.21.82.12.6Surowitz 2015VAS2257.21.81.41.8Jang 2009VAS 18060 to 1808.03.681.41.8Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty1956.01.93.0 31.0 to 5.0 4			-	1.0	1.4	0.5	
NOSE Item52.21.30.40.8Garcia 2011NOSE total6083. 487.237.565.91Kayabasoglu 2015NOSE total18085. 05.1725.02.12Loyo 2018NOSE total42072. 2514.552424.58Most 2006NOSE total16276. 714.812.913.8Surowitz 2015NOSE total4268. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total2257.21.82.12.6Surowitz 2015VAS2257.21.81.41.8Jang 2009VAS 18060 to 1808.0 43.681.0Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty6014. 5 311.0 to 5.0 43.0 31.0 to 5.0 4				1.9	1.4	0.5	1.0
Item5I00.8Garcia 2011NOSE total6083. 487.237.565.91Kayabasoglu 2015NOSE total18085. 05.1725.02.12Loyo 2018NOSE total42072. 2514.552424.58Most 2006NOSE total16276. 714.812.913.8Surowitz 2015NOSE total4268. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total2257.21.82.12.6Surowitz 2015VAS 5427.21.81.41.8Jang 2009VAS 18060 to 1808.03.681.41.8Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty18061.93.0 31.0 to 5.0 4			-	22	13	0.4	
Garcia 2011NOSE total60 total83. 487.23 7.567.565.91Kayabasoglu 2015NOSE total180 total85. 05.17 025.02.12Loyo 2018 Most 2006NOSE total420 total72. 2514.55 2424.58Most 2006 totalNOSE total162 76. 776. 714.8 2.1212.9Surowitz 2015NOSE total42 268. 217.4 221.119.8Surowitz 2015NOSE total225 268. 217.4 221.119.8Surowitz 2015NOSE total225 268. 217.421.119.8Surowitz 2015NOSE total225 27.21.81.41.8Jang 2009 Jang 2009VAS VAS60 to 180 48.0 43.141.8Jang 2010 LotalVAS195 1956.01.92.61.0Extracorporeal septoplasty100 5.0 414. 5.311.0 to 5.0 43.0 31.0 to 5.0 4				2	1.5	0.7	0.8
total487.565.91Kayabasoglu 2015NOSE total180 085. 05.17 025.02.12Loyo 2018 Most 2006NOSE total420 total72. 2514.55 2424.58Most 2006 totalNOSE total162 776. 714.8 712.913.8Surowitz 2015NOSE total42 268. 217.4 221.119.8Surowitz 2015NOSE total22568. 217.4 221.119.8Surowitz 2015NOSE total22568. 217.415.8 2.119.0Surowitz 2015NOSE total2257.21.82.12.6Surowitz 2015VAS 15427.21.81.41.8Jang 2009VAS 18060 to 1808.0 43.141.41.8Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty1005.316.0 43.0 31.0 to 5.0 4	Garcia 2011		60	83.	7.23		
Kayabasoglu 2015NOSE total18085. 05.1725.02.12Loyo 2018NOSE total42072. 2514.552424.58Most 2006NOSE total16276. 714.812.913.8Surowitz 2015NOSE total4268. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total22568. 217.415.819.0Surowitz 2015VAS 5427.21.82.12.6Surowitz 2015VAS60 to 1808.03.681.41.8Jang 2009VAS 18060 to 1808.33.141.01.0Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty5316.043.03.03.05.0						7.56	5.91
$\begin{array}{c c c c c c c c c c c c c c c c c c c $	Kayabasoglu		180		5.17	25.0	0.10
total252424.38Most 2006NOSE total16276. 714.812.913.8Surowitz 2015NOSE total4268. 217.421.119.8Surowitz 2015NOSE total22568. 217.421.119.8Surowitz 2015NOSE total22568. 217.415.819.0Surowitz 2015VAS $^5$ 427.21.82.12.6Surowitz 2015VAS $^5$ 2257.21.81.41.8Jang 2009VAS 18060 to 1808.0 43.68	2015	total		0		25.0	2.12
Itotal25Image: space spac	Loyo 2018	NOSE	420		14.55	24	24.58
total712.913.8SurowitzNOSE4268.17.421.119.82015total2219.019.0SurowitzNOSE22.568.17.415.819.02015total221.82.12.6SurowitzVAS 5427.21.81.41.82015VAS22.57.21.81.41.8SurowitzVAS60 to8.03.681.41.8Jang 2009VAS60 to8.33.141.41.8Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty5316.0 43.0 31.0 to5.0 4						24	24.30
total////SurowitzNOSE4268.17.421.119.82015total268.17.415.819.0SurowitzNOSE22568.17.415.819.02015total27.21.82.12.6SurowitzVAS $^5$ 427.21.81.41.82015VAS2257.21.81.41.8SurowitzVAS60 to8.03.681.41.8Jang 2009VAS60 to8.33.141.41.8Jang 2010VAS1956.01.92.61.0Extracorporeal septoplasty6014.11.0 to 5 $^3$ 3.0 $^3$ 1.0 to 5.0 $^4$	Most 2006		162		14.8	12.9	13.8
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$						12.9	15.0
2015total2 $   -$			42		17.4	21.1	19.8
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$							1910
2015total2 $Surowitz2015VAS 5427.21.82.12.6Surowitz2015VAS2257.21.81.41.8Jang 2009VAS60 to1808.043.68$			225		17.4	15.8	19.0
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		total	40		1.0	0.1	
2015       VAS       Image: Constraint of the second secon		VAS <sup>5</sup>	42	7.2	1.8	2.1	2.6
Jang 2009VAS60 to $180$ 8.0 $4$ 3.68Jang 2009VAS60 to $180$ 8.3 $6$ 3.14Jang 2010VAS1956.01.9Jang 2010VAS1956.01.9Extracorporeal septoplastyMobley 2016NOSE total6014. $5^3$ 11.0 to $16.0^4$ 3.0 $^3$		VAS	225	7.2	1.8	1.4	1.8
Image: Second		VAC	60.40	0.0		2.69	
Jang 2009         VAS         60 to 180         8.3 6         3.14           Jang 2010         VAS         195         6.0         1.9         2.6         1.0           Extracorporeal septoplasty         Mobley 2016         NOSE         60         14.         11.0 to 5 <sup>3</sup> 3.0 <sup>3</sup> 1.0 to 5.0 <sup>4</sup>	Jang 2009	VAS				3.08	
180         6         180           Jang 2010         VAS         195         6.0         1.9         2.6         1.0           Extracorporeal septoplasty         Incomparison         Incomparison         Incomparison         Incomparison         Incomparison           Mobley 2016         NOSE         60         14.         11.0 to         3.0 3         1.0 to           total         5 3         16.0 4         3.0 3         5.0 4	Jang 2000	VAS				3 1 /	
Jang 2010         VAS         195         6.0         1.9         2.6         1.0           Extracorporeal septoplasty	Jang 2007	VA5				5.14	
Extracorporeal septoplastyMobley 2016NOSE6014.11.0 to $3.0^3$ 1.0 tototal $5^3$ 16.0 4 $3.0^3$ $5.0^4$	Jang 2010	VAS			19	2.6	1.0
Mobley 2016NOSE total6014. $5^3$ 11.0 to 16.0 43.0 31.0 to $5.0^4$			175	0.0	1.7	2.0	1.0
total $5^3$ 16.0 <sup>4</sup> $5.0^4$ 5.0 <sup>4</sup>			60	14.	11.0 to		1.0 to
	2010			5 <sup>3</sup>		3.0 3	
10002010   vAS   303   3.0     $1.9$	Gode 2018	VAS	365	3.0		7.9	

 Table 2: Changes in Nasal Obstruction Symptom Evaluation (NOSE) or nasal obstruction visual anlogue scale scores reported by the included studies

<sup>1</sup>No total score reported, individual scores in raw points; <sup>2</sup>Standard deviation; <sup>3</sup> Median; <sup>4</sup> Interquartile range; <sup>5</sup>Nasal obstruction visual anlogue scale;

	Preop ve	perati	Postop	erative	Mean change			
Study	Me an	SD	Mea n	SD	Mea n	Lower 95% CL	Upper 95% CL	
Garcia 2011 <sup>1</sup> ; MCA <sup>2</sup> , cm <sup>2</sup>								
Before constriction	0.3 5	0.2 2	0.67	0.18	0.33	0.21	0.44	
After constriction	0.4 3	0.2 4	0.73	0.17	0.30	0.18	0.42	
Serna 2014 <sup>3</sup>								
Nasal flow (cm <sup>3</sup> /s)								
Group 1	665 .8	109 .4	1111 .6	141. 3	445. 8	393.8	497.8	
Group 2	620 .3	76. 9	1094 .2	168. 8	473. 9	339.4	608.4	
Group 3	862 .7	73. 4	1183 .7	55.6	32 1.0	253.3	388.7	
Nasal Resistances (Pas/cm <sup>3</sup> )								
Group 1	0.2 3	0.0 4	0.14	0.02	-0.09	-0.11	-0.08	
Group 2	0.2 5	0.0 3	0.14	0.02	-0.11	-0.13	-0.09	
Group 3	0.2 2	0.0 2	0.12	0.01	-0.10	-0.12	-0.08	

Table 3: Results of acoustic rhinomanometry

<sup>1</sup> Modified extracorporeal septoplasty; <sup>2</sup> Minimum Cross-sectional Area; <sup>3</sup> Extracorporeal septoplasty

# SUPPLEMENTARY

eTable 1. Methodological quality of the included studies.

Criteria:

- 1 Study question,
- 2 Eligibility criteria and study population;
- 3 Study participants representative of clinical populations of interest;
- 4 All eligible participants enrolled;
- 5 Sample size;
- 6 Intervention clearly described;
- 7 Outcome measures clearly described, valid, and reliable;
- 8 Blinding of outcome assessors;
- 9 Follow-up rate;
- 10 Statistical analysis;
- 11 Multiple outcome measures;

# 12 - Group-level interventions and individual-level outcome efforts

Criteria $^{1} \rightarrow$													
Study $\downarrow$	1	2	3	4	5	6	7	8	9	10	11	12	Total <sup>2</sup>
Andre 2006	Yes	Yes	Yes	Yes	NA	Yes	No	No	Yes	Yes	No	NA	Poor
Asher 2018	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	No	Yes	No	NA	Fair
Boulanger 2013	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Good
Chang 2010	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	Yes	NA	Poor
Garcia 2011	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	NA	Yes	No	NA	Good
Jang 2009	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Fair
Jang 2010	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	Yes	Yes	No	NA	Good
Kayabasoglu 2015	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	Yes	No	NA	Fair
Lee 2014	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Good
Loyo 2018	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Good
Most 2006	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	Yes	NA	NA	Good
Persichetti 2016	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	Yes	Yes	Yes	NA	Good
Srinoglu 2016	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	Yes	No	NA	Good
Surowitz 2015	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	Yes	Yes	NA	Good
Won 2012	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	No	No	NA	Poor
Gerlinger 2017	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	Yes	No	NA	Fair
Gevorgyan 2013	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	No	NA	Poor
Gode 2018	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Good
Gubisch 2005	Yes	Yes	Yes	Yes	NA	Yes	No	No	NA	No	No	NA	Poor
Kantas 2008	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	No	NA	Poor

Karamese 2016	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	Yes	Yes	No	NA	Good
Mendis 2013	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	No	NA	Poor
Mobley 2016	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Good
Numanoglu 1997	Yes	No	Yes	Yes	NA	Yes	No	No	Yes	No	No	NA	Poor
Razaeian 2016	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	Yes	No	NA	Fair
Rimmer 2012	Yes	Yes	Yes	Yes	NA	Yes	No	No	Yes	No	Yes	NA	Fair
Senyuva 1997	Yes	Yes	Yes	Yes	NA	Yes	No	No	Yes	No	No	NA	Poor
Serna 2014	Yes	Yes	Yes	Yes	NA	Yes	Yes	Yes	Yes	Yes	No	NA	Good
Tweedie 2010	Yes	Yes	Yes	Yes	NA	Yes	No	No	NA	No	Yes	NA	Poor
Unsal 2016	Yes	Yes	Yes	Yes	NA	Yes	Yes	NA	Yes	Yes	No	NA	Good
Wilson 2011	Yes	Yes	Yes	Yes	NA	Yes	Yes	No	Yes	No	No	NA	Poor

<sup>1</sup> Individual criteria are valued as 'yes', 'no', or 'NA' (Not applicable or not reported); <sup>2</sup> Total quality is valued as 'poor', 'fair', or 'good'

			Cirk		210,1110110	Complication		<i>.</i> ,			
	Study		Total No. Pt	Infection	Bleeding	Dorsal Irregularity	Other Cosmetic	Other Functional	Unknown (Complications Not Reported)	Revision Surgery	Unknown (Revision rate not reported)
1.	Andre et al, 2006	M-ECS	(114)						NR		NR
2.	Asher et al, 2018	M-ECS	(144)	1/144 (0.7%)						14/144 (9.7%)	
3.	Boulanger et al, 2013	M-ECS	(35)						NR		NR
4.	Chang, 2010	M-ECS	(41)				4/41 (9.8%)			4/41 (9.8%)	
5.	Garcia et al, 2011	M-ECS	(10)						NR		NR
6.	Jang et al, 2010	M-ECS	(27)				1/27				NR
7.	Jang et al, 2009	M-ECS	(45)	4/45		1/45		1/45		1/45	
8.	Kayabasoglu et al, 2015	M-ECS	(78) (33/ <b>45</b> )			G1:1/33 <b>G2: 2/45</b>					NR
9.	Lee et al, 2014	M-ECS	<b>G1: 84</b> G2: 85 Total: 169	1/84		5/84		1/84			NR
10.	Loyo et al, 2018	M-ECS	(71)			4/71					
11.	Most, 2006	M-ECS	(12)						NR		NR
12.	Persichetti et al, 2016	M-ECS	(120)					3/120			NR
13.	Srinoglu et al, 2016	M-ECS	(16)				1/16				NR
14.	Surowitz et al, 2017	M-ECS	(77)					1/77			NR
15.	Won et al, 2012	M-ECS	(25)					1/25			NR

#### eTABLE 2: COMPLICATIONS & REVISIONS (Modified ECS)

#### eTABLE 2 (contd): COMPLICATIONS & REVISIONS (ECS)

						Complication	S				
	Study		Total No. Pt	Infection	Bleeding	Dorsal Irregularity	Other Cosmetic	Other Functional	Unknown (Complications Not Reported)	Revision Surgery	Unknown (Revision rate not reported)
1.	Gerlinger et al, 2007	ECS	(16)		1/16	2/16		3/16			NR
2.	Gevorgyan et al, 2013	ECS	(17)	1/17				2/17			
3.	Gode et al, 2018	ECS	(40); <b>G1: 20</b>			1/20 (5%)		1/20 (5%)		1/20 (5%)	
4.	Gubisch, 2005	ECS	(567)(459/108)	1 (1/0)		50(38/12)		8 (6/2)		28 pt (20-4%/ 8-7%)	
5.	Kantas et al, 2008	ECS	(64)			2/64	2/64	1/64			NR
6.	Karamese et al, 2016	ECS	(19)						NR	1/19	
7.	Mendis et al, 2013	ECS	(46)	1/46	1/46					2/46	
8.	Mobley et al, 2016	ECS	(55)						NR		NR
9.	Numanoglu 1996	ECS	(45)					5/45		1/45	
10.	Rezaeian et al, 2016	ECS	(110)				0/110	0/110		5/110	
11.	Rimmer et al, 2012	ECS	(102)	2/102							NR
12.	Senyuva et al, 1997	ECS	(17)		4/17					0/17	
13.	Serna et al, 2014	ECS	(26)				0/26	0/26			NR
14.	Tweedie et al, 2010	ECS	(50)	1/50		4/50				7/50	
15.	Wilson et al, 2011	ECS	(46)	3/46				1/46			NR
16.	Unsal et al, 2016	ECS	(32)						NR		NR